Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID A EICHENBAUM

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1144251356
CMS profile
279088
Location
ST PETERSBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$328,544.90

325 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 5 of 7; records 201–250 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID A EICHENBAUM

NPI 1144251356 · CMS profile ID 279088

Allopathic & Osteopathic Physicians / Ophthalmology

ST PETERSBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 7; records 201–250 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID A EICHENBAUM, NPI 1144251356, CMS profile ID 279088. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DAVID A EICHENBAUM, NPI 1144251356, CMS profile ID 279088. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DAVID A EICHENBAUM, NPI 1144251356, CMS profile ID 279088, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 325 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144251356?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

325 matching records · $328,544.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 325 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 325.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $527.9806/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289931 CMS
Allergan Inc. $8.0006/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289935 CMS
Allergan Inc. $118.1206/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289939 CMS
Allergan Inc. $30.0006/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289943 CMS
Allergan Inc. $131.5506/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289945 CMS
Genentech USA, Inc. $2.1306/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681325469 CMS
Carl Zeiss Meditec, Inc. $69.7605/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693202403 CMS
Allergan Inc. $15.4305/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289899 CMS
Celgene Corporation $310.0005/30/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672812978 CMS
Spark Therapeutics, Inc. $102.5605/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682145683 CMS
Alimera Sciences, Inc. $7.8005/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691753755 CMS
Dutch Ophthalmic, USA $13.3805/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698426241 CMS
Dutch Ophthalmic, USA $732.3605/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698427373 CMS
Dutch Ophthalmic, USA $5,000.0005/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698427463 CMS
Novartis Pharmaceuticals Corporation $11.7705/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797689 CMS
Novartis Pharmaceuticals Corporation $146.9605/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797776 CMS
Novartis Pharmaceuticals Corporation $474.4405/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797783 CMS
Novartis Pharmaceuticals Corporation $8,200.0005/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797787 CMS
Novartis Pharmaceuticals Corporation $100.0005/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797795 CMS
Novartis Pharmaceuticals Corporation $188.3805/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797800 CMS
Genentech USA, Inc. $120.6705/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681242251 CMS
Bausch & Lomb, a division of Bausch Health US, LLC $21.3305/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684408149 CMS
EyePoint Pharmaceuticals US, Inc. $2,250.0005/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698071921 CMS
Allergan Inc. $3,000.0005/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289891 CMS
Allergan Inc. $76.1505/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289895 CMS
Novartis Pharmaceuticals Corporation $762.9305/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797827 CMS
Novartis Pharmaceuticals Corporation $5,125.0005/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797833 CMS
Novartis Pharmaceuticals Corporation $113.4305/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797839 CMS
Genentech USA, Inc. $113.6004/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681278271 CMS
Genentech USA, Inc. $702.0804/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681323525 CMS
Genentech USA, Inc. $6,200.0004/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 857128221 CMS
Allergan Inc. $22.0704/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670289887 CMS
Dutch Ophthalmic, USA $24.2804/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698426405 CMS
Dutch Ophthalmic, USA $275.0804/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698427271 CMS
Dutch Ophthalmic, USA $6,500.0004/29/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698427469 CMS
EyePoint Pharmaceuticals US, Inc. $14.0604/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698071927 CMS
EyePoint Pharmaceuticals US, Inc. $24.3804/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698071931 CMS
Genentech, Inc. $24.4704/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681169931 CMS
Novartis Pharmaceuticals Corporation $49.0404/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658797659 CMS
Genentech, Inc. $83.9604/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681166631 CMS
Ocular Therapeutix, Inc. $14.1004/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704574989 CMS
Ocular Therapeutix, Inc. $14.1004/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704574993 CMS
Celgene Corporation $930.0004/25/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672798377 CMS
Regeneron Healthcare Solutions, Inc. $116.8304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673373495 CMS
Genentech USA, Inc. $2.1104/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681248361 CMS
Alimera Sciences, Inc. $19.6604/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691753727 CMS
Genentech USA, Inc. $550.0004/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 857128235 CMS
Genentech USA, Inc. $1,230.0804/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681172269 CMS
Genentech USA, Inc. $29.4404/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681264807 CMS
Genentech USA, Inc. $125.5404/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681302605 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $328,544.90 325
PY2020 $150,751.58 136
PY2021 $198,330.36 214
PY2022 $272,409.36 261
PY2023 $211,910.52 217
PY2024 $286,315.78 300
PY2025 $244,966.76 245

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,485.88 4
PY2025 Principal investigator $10,627,254.21 800
PY2024 Recipient $8,932.27 4
PY2024 Principal investigator $6,627,967.87 343
PY2023 Recipient $1,925.65 3
PY2023 Principal investigator $3,430,849.09 192
PY2022 Principal investigator $3,798,346.45 192
PY2021 Recipient $12,906.03 5
PY2021 Principal investigator $3,082,081.64 207
PY2020 Recipient $12,431.94 6
PY2020 Principal investigator $3,643,159.02 144
PY2019 Recipient $4,281.10 1
PY2019 Principal investigator $1,501,447.49 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

804 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $4,796.00 12/30/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600451
Principal investigator 1 Janssen Research & Development, LLC $8,543.00 12/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175392016
Principal investigator 1 Ocular Therapeutix, Inc. $3,430.77 12/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236304
Principal investigator 1 Genentech, Inc. $4,155.00 12/26/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600456
Principal investigator 1 Ocular Therapeutix, Inc. $15,517.80 12/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236297
Principal investigator 1 Ocular Therapeutix, Inc. $88,096.50 12/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,953.25 12/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,198.48 12/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,198.48 12/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280170
Principal investigator 1 Genentech, Inc. $140.00 12/19/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600419
Principal investigator 1 Genentech, Inc. $454.00 12/19/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600424
Principal investigator 1 Genentech, Inc. $347.20 12/19/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600430
Principal investigator 1 Genentech, Inc. $576.80 12/19/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600434
Principal investigator 1 Genentech, Inc. $252.00 12/19/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600438
Principal investigator 1 Genentech, Inc. $434.00 12/19/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600443
Principal investigator 1 Genentech, Inc. $9,428.00 12/19/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,272.72 12/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,089.93 12/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,842.63 12/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278220
Principal investigator 1 SANOFI US SERVICES INC. $33,044.70 12/19/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
Age-related macular degeneration No dispute reported 06/30/2026 1226100339
Principal investigator 1 SANOFI US SERVICES INC. $5,290.35 12/19/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
Age-related macular degeneration No dispute reported 06/30/2026 1226100346
Principal investigator 1 SANOFI US SERVICES INC. $1,904.95 12/19/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Fl
Age-related macular degeneration No dispute reported 06/30/2026 1226107520
Principal investigator 1 Ocular Therapeutix, Inc. $3,014.95 12/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236294
Principal investigator 1 Genentech, Inc. $4,302.00 12/16/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646720
Principal investigator 1 Janssen Research & Development, LLC $36,259.00 12/15/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175392049
Principal investigator 1 Genentech, Inc. $3,472.00 12/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211637199
Principal investigator 1 Janssen Research & Development, LLC $4,663.00 12/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175391904
Principal investigator 1 Genentech, Inc. $4,051.00 12/11/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646657
Principal investigator 1 Ocular Therapeutix, Inc. $4,919.90 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.36 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.60 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $222.86 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $487.29 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $572.88 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $609.84 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $185.69 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.88 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $249.48 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $482.84 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.40 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71.31 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.14 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.91 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.90 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.82 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $646.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.14 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.82 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.60 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.97 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.36 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.82 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $646.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.90 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.97 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.91 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.38 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.60 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.14 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $646.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $151.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.90 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.97 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.91 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.36 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.60 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.90 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $244.20 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71.31 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $76.56 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.82 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.14 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $646.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.97 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.91 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.36 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.60 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.82 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.14 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.13 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $646.80 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.90 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.97 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.91 12/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184270113
Principal investigator 1 Genentech, Inc. $171,725.00 12/08/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646715
Principal investigator 1 Genentech, Inc. $1,828.00 12/05/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646652
Principal investigator 1 Genentech, Inc. $13,358.00 12/04/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600426
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,054,794.52 12/04/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration No dispute reported 06/30/2026 1190301991
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634437
Principal investigator 1 Genentech, Inc. $10,000.00 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211637204
Principal investigator 1 Genentech, Inc. $2,660.00 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211637208
Principal investigator 1 Genentech, Inc. $1,000.00 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211637212
Principal investigator 1 Genentech, Inc. $2,000.00 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FLORIDA
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211637216
Principal investigator 1 Ocular Therapeutix, Inc. $1,110.00 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236267
Principal investigator 1 Ocular Therapeutix, Inc. $87,183.60 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236272
Principal investigator 1 Ocular Therapeutix, Inc. $28,193.40 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236278
Principal investigator 1 Ocular Therapeutix, Inc. $755.54 12/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236282
Principal investigator 1 Genentech, Inc. $134.97 11/26/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600382
Principal investigator 1 Janssen Research & Development, LLC $888.00 11/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175391899
Principal investigator 1 Ocular Therapeutix, Inc. $3,770.49 11/21/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236251
Principal investigator 1 Ocular Therapeutix, Inc. $3,014.95 11/21/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236255
Principal investigator 1 Ocular Therapeutix, Inc. $18,385.20 11/21/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236259
Principal investigator 1 Ocular Therapeutix, Inc. $35,819.00 11/21/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236263
Principal investigator 1 Genentech, Inc. $2,048.00 11/20/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600399
Principal investigator 1 Genentech, Inc. $1,067.13 11/20/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600411
Principal investigator 1 Ocular Therapeutix, Inc. $3,014.95 11/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,272.72 11/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,098.12 11/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,089.93 11/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,953.25 11/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,198.48 11/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262165
Principal investigator 1 Roche TCRC, Inc. $8,455.00 11/17/2025 Non-covered Recipient Entity
Pautler,Cohen,Findlay and Eichenbaum MD's
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211637230
Principal investigator 1 Genentech, Inc. $904.40 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600360
Principal investigator 1 Genentech, Inc. $11,415.00 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600365
Principal investigator 1 Genentech, Inc. $3,805.00 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600369
Principal investigator 1 Genentech, Inc. $848.28 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600373
Principal investigator 1 Genentech, Inc. $6,660.00 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600377
Principal investigator 1 Genentech, Inc. $434.00 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600385
Principal investigator 1 Genentech, Inc. $4,155.00 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600394
Principal investigator 1 Genentech, Inc. $358.83 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600404
Principal investigator 1 Genentech, Inc. $454.00 11/14/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600415
Principal investigator 1 Genentech, Inc. $405.65 11/14/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646702
Principal investigator 1 Genentech, Inc. $6,365.00 11/14/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211646742
Principal investigator 1 SANOFI US SERVICES INC. $8,623.00 11/14/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
Age-related macular degeneration No dispute reported 06/30/2026 1226100397
Principal investigator 1 Genentech, Inc. $4,131.36 11/12/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646710
Principal investigator 1 Ocular Therapeutix, Inc. $6,183.90 11/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236240
Principal investigator 1 Genentech, Inc. $4,818.00 11/06/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600390
Principal investigator 1 ABBVIE INC. $15,844.40 11/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202520051
Principal investigator 1 Janssen Research & Development, LLC $9,105.00 11/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175391994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,436.50 11/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184257019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,480.10 11/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184257021
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634435
Principal investigator 1 Genentech, Inc. $4,155.00 10/29/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600354
Principal investigator 1 Genentech, Inc. $126.00 10/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211637195
Principal investigator 1 Genentech, Inc. $2,689.00 10/29/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646707
Principal investigator 1 Ocular Therapeutix, Inc. $135,418.70 10/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236224
Principal investigator 1 Ocular Therapeutix, Inc. $60,367.50 10/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236227
Principal investigator 1 Ocular Therapeutix, Inc. $64,069.20 10/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236232
Principal investigator 1 ABBVIE INC. $80.76 10/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202518857
Principal investigator 1 Janssen Research & Development, LLC $1,534.00 10/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175392031
Principal investigator 1 KYOWA KIRIN, INC. $3,650.93 10/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221813720
Principal investigator 1 KYOWA KIRIN, INC. $6,505.53 10/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221813726
Principal investigator 1 KYOWA KIRIN, INC. $4,241.13 10/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221813734
Principal investigator 1 KYOWA KIRIN, INC. $3,706.93 10/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221813742
Principal investigator 1 KYOWA KIRIN, INC. $3,962.53 10/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221813751
Principal investigator 1 Genentech, Inc. $5,425.00 10/24/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600356
Principal investigator 1 Genentech, Inc. $12,936.00 10/17/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,098.12 10/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251295
Principal investigator 1 SANOFI US SERVICES INC. $11,700.00 10/17/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
Age-related macular degeneration No dispute reported 06/30/2026 1226100451
Principal investigator 1 Genentech, Inc. $6,267.00 10/16/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600349
Principal investigator 1 Genentech, Inc. $4,375.00 10/16/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646639
Principal investigator 1 Ocular Therapeutix, Inc. $6,220.95 10/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236219
Principal investigator 1 Genentech, Inc. $4,790.00 10/09/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600343
Principal investigator 1 Genentech, Inc. $6,098.00 10/09/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646647
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/09/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA (SAINT PETERSBURG)
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238349
Principal investigator 1 Ocular Therapeutix, Inc. $4,248.15 10/08/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236215
Principal investigator 1 Genentech, Inc. $10,431.35 10/07/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646697
Principal investigator 1 Genentech, Inc. $9,618.00 10/06/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646630
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634433
Principal investigator 1 Genentech, Inc. $6,267.00 10/01/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600346
Principal investigator 1 Janssen Research & Development, LLC $8,543.00 09/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175392043
Principal investigator 1 Genentech, Inc. $31,873.00 09/26/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646634
Principal investigator 1 Ocular Therapeutix, Inc. $1,836.80 09/26/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236211
Principal investigator 1 Genentech, Inc. $1,385.00 09/24/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600315
Principal investigator 1 Genentech, Inc. $11,629.00 09/24/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600331
Principal investigator 1 Genentech, Inc. $5,312.00 09/24/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211646736
Principal investigator 1 Ocular Therapeutix, Inc. $2,220.00 09/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236206
Recipient F. Hoffmann-La Roche AG $1,188.14 09/19/2025 Covered Recipient Physician STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211535292
Principal investigator 1 Janssen Research & Development, LLC $690.00 09/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391958
Principal investigator 1 KYOWA KIRIN, INC. $3,272.82 09/15/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810640
Principal investigator 1 KYOWA KIRIN, INC. $3,318.00 09/15/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810646
Principal investigator 1 KYOWA KIRIN, INC. $9,524.75 09/15/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810653
Principal investigator 1 Genentech, Inc. $4,066.00 09/11/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,089.93 09/11/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,953.25 09/11/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,272.72 09/11/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236007
Principal investigator 1 Ocular Therapeutix, Inc. $7,121.80 09/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236189
Principal investigator 1 Ocular Therapeutix, Inc. $2,424.80 09/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236192
Principal investigator 1 Ocular Therapeutix, Inc. $6,837.60 09/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236197
Principal investigator 1 Ocular Therapeutix, Inc. $2,548.00 09/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236201
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $226.95 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410418
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $880.00 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410606
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $124.62 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410678
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410848
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $124.62 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410880
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,227.30 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410932
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $226.95 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411150
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $124.62 09/08/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225411170
Principal investigator 1 Ocular Therapeutix, Inc. $25,489.80 09/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236184
Principal investigator 1 Genentech, Inc. $3,805.00 09/04/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600311
Principal investigator 1 Genentech, Inc. $2,500.00 09/04/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600319
Principal investigator 1 Genentech, Inc. $7,793.00 09/04/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600324
Principal investigator 1 Genentech, Inc. $3,805.00 09/04/2025 Non-covered Recipient Entity
EIRVERA LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211600339
Principal investigator 1 Genentech, Inc. $146.00 09/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211637190
Principal investigator 1 Ocular Therapeutix, Inc. $3,809.90 09/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236153
Principal investigator 1 Ocular Therapeutix, Inc. $12,689.90 09/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236158
Principal investigator 1 Ocular Therapeutix, Inc. $6,029.90 09/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236163
Principal investigator 1 Ocular Therapeutix, Inc. $23,983.40 09/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236168
Principal investigator 1 Ocular Therapeutix, Inc. $19,700.80 09/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236171
Principal investigator 1 Ocular Therapeutix, Inc. $2,548.00 09/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236176
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634431
Principal investigator 1 Janssen Research & Development, LLC $8,205.00 08/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175392010
Principal investigator 1 ABBVIE INC. $37,760.14 08/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506075
Principal investigator 1 Genentech, Inc. $914.00 08/27/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646625
Principal investigator 1 Janssen Research & Development, LLC $2,754.94 08/25/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391946
Principal investigator 1 Janssen Research & Development, LLC $10,939.00 08/25/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391986
Principal investigator 1 Ocular Therapeutix, Inc. $272,798.10 08/22/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236148
Principal investigator 1 Janssen Research & Development, LLC $4,663.00 08/20/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175392020
Principal investigator 1 KYOWA KIRIN, INC. $8,577.24 08/20/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221809663
Principal investigator 1 ABBVIE INC. $7,572.56 08/13/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY EICHENBAUM WHITE AND CRANE MDS PA
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202504459
Principal investigator 1 Ocular Therapeutix, Inc. $5,152.00 08/06/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236140
Principal investigator 1 Ocular Therapeutix, Inc. $118,293.30 08/06/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236143
Principal investigator 1 Janssen Research & Development, LLC $19,445.00 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175392037
Principal investigator 1 KYOWA KIRIN, INC. $5,379.56 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808630
Principal investigator 1 KYOWA KIRIN, INC. $5,833.02 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808685
Principal investigator 1 KYOWA KIRIN, INC. $5,491.56 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808693
Principal investigator 1 KYOWA KIRIN, INC. $9,854.73 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808728
Principal investigator 1 KYOWA KIRIN, INC. $4,241.13 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808760
Principal investigator 1 KYOWA KIRIN, INC. $5,564.33 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808889
Principal investigator 1 KYOWA KIRIN, INC. $5,833.02 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808936
Principal investigator 1 KYOWA KIRIN, INC. $8,419.47 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808967
Principal investigator 1 KYOWA KIRIN, INC. $5,564.33 08/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808986
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634429
Principal investigator 1 KYOWA KIRIN, INC. $5,896.53 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807928
Principal investigator 1 KYOWA KIRIN, INC. $4,032.53 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807934
Principal investigator 1 KYOWA KIRIN, INC. $5,896.53 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807941
Principal investigator 1 KYOWA KIRIN, INC. $3,512.33 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807947
Principal investigator 1 KYOWA KIRIN, INC. $3,512.33 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807956
Principal investigator 1 Ocular Therapeutix, Inc. $6,123.60 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.14 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.82 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.80 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.60 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $249.48 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $222.86 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $115.88 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $185.71 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $213.93 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $609.84 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.20 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.14 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $516.82 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.80 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.36 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.91 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.97 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.90 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $646.80 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.36 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.91 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.97 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $226.90 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $646.80 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.00 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71.31 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71.31 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.13 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $487.29 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $88.44 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $157.57 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.63 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $264.60 07/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184221898
Principal investigator 1 Genentech, Inc. $39,029.00 07/28/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646693
Principal investigator 1 Janssen Research & Development, LLC $5,990.00 07/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175392005
Principal investigator 1 Ocular Therapeutix, Inc. $7,454.95 07/25/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236134
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/24/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220634519
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/24/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220634521
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/24/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220634523
Principal investigator 1 Janssen Research & Development, LLC $4,663.00 07/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175391976
Principal investigator 1 Janssen Research & Development, LLC $610.00 07/18/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175391920
Principal investigator 1 Genentech, Inc. $25,119.00 07/07/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646623
Principal investigator 1 Janssen Research & Development, LLC $16,748.00 07/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391970
Principal investigator 1 Ocular Therapeutix, Inc. $15,844.50 07/02/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236120
Principal investigator 1 Ocular Therapeutix, Inc. $3,168.90 07/02/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236125
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634427
Principal investigator 1 Genentech, Inc. $49,448.00 06/25/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646557
Principal investigator 1 Genentech, Inc. $4,296.00 06/25/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646571
Principal investigator 1 Genentech, Inc. $3,926.00 06/23/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646562
Principal investigator 1 Ocular Therapeutix, Inc. $6,096.60 06/23/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236088
Principal investigator 1 Genentech, Inc. $11,251.00 06/17/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211646723
Principal investigator 1 Genentech, Inc. $1,257.00 06/11/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646565
Principal investigator 1 Janssen Research & Development, LLC $63,398.00 06/09/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391891
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 06/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806455
Principal investigator 1 KYOWA KIRIN, INC. $1,106.00 06/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806465
Principal investigator 1 KYOWA KIRIN, INC. $7,640.04 06/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806471
Principal investigator 1 KYOWA KIRIN, INC. $566.05 06/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806479
Principal investigator 1 Genentech, Inc. $22,428.00 06/02/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646662
Principal investigator 1 Janssen Research & Development, LLC $3,389.00 06/02/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391927
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634425
Principal investigator 1 Ocular Therapeutix, Inc. $4,986.80 05/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236084
Principal investigator 1 KYOWA KIRIN, INC. $1,106.00 05/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806167
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 05/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806239
Principal investigator 1 KYOWA KIRIN, INC. $8,577.24 05/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806247
Principal investigator 1 KYOWA KIRIN, INC. $8,577.24 05/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806254
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 05/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806263
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,207.99 05/28/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407774
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 05/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805880
Principal investigator 1 KYOWA KIRIN, INC. $566.05 05/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805889
Principal investigator 1 KYOWA KIRIN, INC. $1,702.40 05/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805958
Principal investigator 1 Ocular Therapeutix, Inc. $7,121.80 05/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236071
Principal investigator 1 Ocular Therapeutix, Inc. $3,014.95 05/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236076
Principal investigator 1 Ocular Therapeutix, Inc. $9,506.70 05/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236080
Principal investigator 1 Janssen Research & Development, LLC $3,100.00 05/26/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175391939
Principal investigator 1 Alexion Pharmaceuticals, Inc. $1,300.00 05/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TAMPA BAY PL
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) No dispute reported 06/30/2026 1185543450
Principal investigator 1 Janssen Research & Development, LLC $4,663.00 05/23/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175392053
Principal investigator 1 Ocular Therapeutix, Inc. $7,121.80 05/23/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236064
Principal investigator 1 Ocular Therapeutix, Inc. $7,121.80 05/23/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236068
Principal investigator 1 KYOWA KIRIN, INC. $566.05 05/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805711
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 05/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805720
Principal investigator 1 Ocular Therapeutix, Inc. $56,770.40 05/16/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236054
Principal investigator 1 KYOWA KIRIN, INC. $566.05 05/15/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805426
Principal investigator 1 Genentech, Inc. $3,008.00 05/14/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646608
Principal investigator 1 Ocular Therapeutix, Inc. $22,324.50 05/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236045
Principal investigator 1 Ocular Therapeutix, Inc. $4,440.00 05/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236050
Principal investigator 1 KYOWA KIRIN, INC. $1,106.00 05/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805308
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 05/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805316
Principal investigator 1 Ocular Therapeutix, Inc. $11,691.40 05/09/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236037
Principal investigator 1 Ocular Therapeutix, Inc. $9,026.75 05/09/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236041
Recipient F. Hoffmann-La Roche AG $414.17 05/08/2025 Covered Recipient Physician STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211535288
Recipient F. Hoffmann-La Roche AG $2,130.00 05/04/2025 Covered Recipient Physician Real-world treatment patterns in patients with macular edema (ME) secondary to non-infectious uveitis (NIU) in the United States No dispute reported 06/30/2026 1211535296
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634423
Principal investigator 1 KYOWA KIRIN, INC. $5,379.56 05/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805017
Principal investigator 1 KYOWA KIRIN, INC. $8,419.47 05/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805025
Principal investigator 1 KYOWA KIRIN, INC. $5,491.56 05/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805033
Principal investigator 1 KYOWA KIRIN, INC. $8,419.47 05/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805043
Principal investigator 1 KYOWA KIRIN, INC. $5,379.56 05/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805052
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 04/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804938
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 04/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804945
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 04/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804952
Principal investigator 1 KYOWA KIRIN, INC. $566.05 04/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804960
Principal investigator 1 Ocular Therapeutix, Inc. $44,719.20 04/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236033
Principal investigator 1 Roche TCRC, Inc. $6,556.00 04/30/2025 Non-covered Recipient Entity
Pautler,Cohen,Findlay and Eichenbaum MD's
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211637241
Principal investigator 1 Genentech, Inc. $4,946.00 04/29/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646680
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,207.99 04/28/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404974
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,585.32 04/28/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405930
Principal investigator 1 Janssen Research & Development, LLC $11,578.00 04/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391952
Principal investigator 1 KYOWA KIRIN, INC. $4,980.91 04/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803731
Principal investigator 1 KYOWA KIRIN, INC. $5,858.13 04/28/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803748
Principal investigator 1 Genentech, Inc. $4,308.00 04/25/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646588
Principal investigator 1 KYOWA KIRIN, INC. $1,479.60 04/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803626
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 04/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803634
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $648.01 04/23/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225404554
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,000.00 04/23/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225404950
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $730.78 04/23/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225404952
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $730.78 04/23/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225405100
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $188.41 04/23/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225405188
Principal investigator 1 Genentech, Inc. $914.00 04/23/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646595
Principal investigator 1 Janssen Research & Development, LLC $6,139.00 04/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391910
Principal investigator 1 Genentech, Inc. $267.79 04/16/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646685
Principal investigator 1 KYOWA KIRIN, INC. $3,454.98 04/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803259
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 04/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803265
Principal investigator 1 Genentech, Inc. $22,270.00 04/09/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211637177
Principal investigator 1 Genentech, Inc. $12,205.00 04/08/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646616
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $345.00 04/04/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404399
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $275.00 04/04/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405426
Principal investigator 1 Genentech, Inc. $126.00 04/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211637182
Principal investigator 1 Genentech, Inc. $86.84 04/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211637186
Principal investigator 1 KYOWA KIRIN, INC. $566.05 04/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803054
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 04/04/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,000.00 04/02/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,260.00 04/02/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181048
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634421
Principal investigator 1 Genentech, Inc. $650.00 04/01/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646605
Principal investigator 1 Genentech, Inc. $4,946.00 04/01/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646675
Principal investigator 1 KYOWA KIRIN, INC. $9,095.67 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802528
Principal investigator 1 KYOWA KIRIN, INC. $3,036.33 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802536
Principal investigator 1 KYOWA KIRIN, INC. $4,980.91 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802543
Principal investigator 1 KYOWA KIRIN, INC. $5,426.11 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802551
Principal investigator 1 KYOWA KIRIN, INC. $5,146.13 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802560
Principal investigator 1 KYOWA KIRIN, INC. $3,556.53 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802572
Principal investigator 1 KYOWA KIRIN, INC. $3,556.53 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802579
Principal investigator 1 KYOWA KIRIN, INC. $8,710.81 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803014
Principal investigator 1 KYOWA KIRIN, INC. $8,710.81 04/01/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221803023
Recipient F. Hoffmann-La Roche AG $753.57 03/31/2025 Covered Recipient Physician Real-world treatment patterns in patients with macular edema (ME) secondary to non-infectious uveitis (NIU) in the United States No dispute reported 06/30/2026 1211535299
Principal investigator 1 Janssen Research & Development, LLC $8,205.00 03/31/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391981
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,585.32 03/27/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404147
Principal investigator 1 Genentech, Inc. $7,273.00 03/26/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646611
Principal investigator 1 Ocular Therapeutix, Inc. $44,517.20 03/26/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236116
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $730.78 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Medical Group
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225403483
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,000.00 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Medical Group
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225403729
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $188.41 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Medical Group
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225403973
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $648.01 03/25/2025 Non-covered Recipient Entity
Retina Northwest PC
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225404954
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $730.78 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Medical Group
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225405190
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634413
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634415
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634417
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 03/25/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634419
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,403.11 03/24/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405932
Principal investigator 1 KYOWA KIRIN, INC. $566.05 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802421
Principal investigator 1 KYOWA KIRIN, INC. $1,106.00 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802426
Principal investigator 1 KYOWA KIRIN, INC. $1,370.45 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802432
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802442
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802450
Principal investigator 1 KYOWA KIRIN, INC. $5,714.85 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802458
Principal investigator 1 KYOWA KIRIN, INC. $8,577.24 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802466
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 03/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802474
Principal investigator 1 Genentech, Inc. $914.00 03/21/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646591
Principal investigator 1 Ocular Therapeutix, Inc. $21,218.40 03/21/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236104
Principal investigator 1 Ocular Therapeutix, Inc. $2,808.40 03/21/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236108
Principal investigator 1 Genentech, Inc. $17,139.78 03/20/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646599
Principal investigator 1 Genentech, Inc. $13,002.10 03/20/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646602
Principal investigator 1 Genentech, Inc. $5,812.67 03/20/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646671
Principal investigator 1 Genentech, Inc. $6,061.00 03/20/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211646731
Principal investigator 1 KYOWA KIRIN, INC. $7,279.04 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802198
Principal investigator 1 KYOWA KIRIN, INC. $7,640.04 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802206
Principal investigator 1 KYOWA KIRIN, INC. $8,427.45 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802213
Principal investigator 1 KYOWA KIRIN, INC. $7,638.75 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802220
Principal investigator 1 KYOWA KIRIN, INC. $7,640.04 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802225
Principal investigator 1 KYOWA KIRIN, INC. $7,640.04 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802241
Principal investigator 1 KYOWA KIRIN, INC. $6,535.56 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802249
Principal investigator 1 KYOWA KIRIN, INC. $7,314.19 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802261
Principal investigator 1 KYOWA KIRIN, INC. $566.05 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802269
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802275
Principal investigator 1 KYOWA KIRIN, INC. $7,263.63 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 03/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184174940
Principal investigator 1 Janssen Research & Development, LLC $8,570.00 03/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175391963
Principal investigator 1 Janssen Research & Development, LLC $10,100.00 03/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175392060
Principal investigator 1 KYOWA KIRIN, INC. $3,275.39 03/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802054
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 03/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802063
Principal investigator 1 KYOWA KIRIN, INC. $1,106.00 03/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802071
Principal investigator 1 Ocular Therapeutix, Inc. $70,779.60 03/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.17 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.72 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.96 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.60 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.17 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.72 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.96 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.22 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.21 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $178.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.09 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.72 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.96 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.60 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.17 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.72 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $178.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.95 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $305.20 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.60 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.17 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.09 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.87 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.96 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.95 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.22 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.09 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $178.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.95 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $305.20 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.60 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.17 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.72 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.96 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.09 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $178.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.87 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.22 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.21 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.87 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.95 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.95 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $305.20 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.87 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.96 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.87 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $178.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.22 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.21 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.22 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.21 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.09 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184168998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $178.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.95 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $356.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $227.72 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.96 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $305.20 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.60 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.21 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.60 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.17 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169330
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.22 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.21 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $305.20 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $349.66 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.87 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $289.47 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.17 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.09 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.68 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $178.45 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $220.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.09 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $287.91 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.87 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.95 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170380
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.22 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.21 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $305.20 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.70 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.60 03/07/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170394
Principal investigator 1 KYOWA KIRIN, INC. $3,486.53 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801793
Principal investigator 1 KYOWA KIRIN, INC. $3,230.93 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801802
Principal investigator 1 KYOWA KIRIN, INC. $9,095.67 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801810
Principal investigator 1 KYOWA KIRIN, INC. $8,710.81 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801817
Principal investigator 1 KYOWA KIRIN, INC. $5,426.11 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801829
Principal investigator 1 KYOWA KIRIN, INC. $9,095.67 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801839
Principal investigator 1 KYOWA KIRIN, INC. $4,980.91 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801846
Principal investigator 1 KYOWA KIRIN, INC. $8,710.81 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801856
Principal investigator 1 KYOWA KIRIN, INC. $9,095.67 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801864
Principal investigator 1 KYOWA KIRIN, INC. $4,980.91 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801871
Principal investigator 1 KYOWA KIRIN, INC. $5,426.11 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801880
Principal investigator 1 KYOWA KIRIN, INC. $9,095.67 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801888
Principal investigator 1 KYOWA KIRIN, INC. $5,426.11 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801896
Principal investigator 1 KYOWA KIRIN, INC. $3,036.33 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801906
Principal investigator 1 Ocular Therapeutix, Inc. $4,093.60 03/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236093
Principal investigator 1 Janssen Research & Development, LLC $49,636.00 03/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391915
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634411
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,403.11 02/28/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404790
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,207.99 02/27/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404976
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,403.11 02/27/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405228
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,207.99 02/27/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405230
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,403.11 02/27/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225405934
Principal investigator 1 Roche TCRC, Inc. $1,207.00 02/24/2025 Non-covered Recipient Entity
Pautler,Cohen,Findlay and Eichenbaum MD's
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211637220
Principal investigator 1 Janssen Research & Development, LLC $3,064.00 02/21/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175392065
Principal investigator 1 Genentech, Inc. $5,615.73 02/19/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646668
Principal investigator 1 Genentech, Inc. $2,477.11 02/19/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211646727
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 02/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801233
Principal investigator 1 KYOWA KIRIN, INC. $2,545.24 02/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801240
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 02/19/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801249
Principal investigator 1 Genentech, Inc. $4,255.00 02/18/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211646581
Principal investigator 1 Genentech, Inc. $39,499.00 02/18/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211646665
Principal investigator 1 Janssen Research & Development, LLC $1,366.00 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175392000
Principal investigator 1 KYOWA KIRIN, INC. $6,223.22 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801168
Principal investigator 1 KYOWA KIRIN, INC. $7,122.60 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801176
Principal investigator 1 KYOWA KIRIN, INC. $3,132.11 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801186
Principal investigator 1 KYOWA KIRIN, INC. $7,640.04 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801192
Principal investigator 1 KYOWA KIRIN, INC. $566.05 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801197
Principal investigator 1 KYOWA KIRIN, INC. $1,105.99 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801204
Principal investigator 1 KYOWA KIRIN, INC. $3,096.98 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801214
Principal investigator 1 KYOWA KIRIN, INC. $4,491.27 02/17/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801222
Principal investigator 1 KYOWA KIRIN, INC. $7,640.04 02/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801108
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 02/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801116
Principal investigator 1 KYOWA KIRIN, INC. $7,640.04 02/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801123
Principal investigator 1 KYOWA KIRIN, INC. $1,106.00 02/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801129
Principal investigator 1 KYOWA KIRIN, INC. $5,714.85 02/14/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801136
Principal investigator 1 Alcon Research LLC $2,021.60 02/13/2025 Non-covered Recipient Entity
Pautler Cohen Findlay Eichenbaum
A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1220912858
Principal investigator 1 Alcon Research LLC $325.00 02/13/2025 Non-covered Recipient Entity
Pautler Cohen Findlay Eichenbaum
A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1220912860
Principal investigator 1 Alexion Pharmaceuticals, Inc. $111,787.98 02/12/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICH
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) No dispute reported 06/30/2026 1185543448
Principal investigator 1 KYOWA KIRIN, INC. $566.05 02/06/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800829
Principal investigator 1 Ocular Therapeutix, Inc. $7,121.80 02/05/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236017
Principal investigator 1 Genentech, Inc. $935.07 02/04/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646584
Principal investigator 1 Genentech, Inc. $6,944.00 02/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211637172
Principal investigator 1 Janssen Research & Development, LLC $27,650.00 02/03/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391933
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634405
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 02/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634407
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 02/01/2025 Non-covered Recipient Entity
Retina Vitreous Associates Of Florida-Saint Petersburg
-Ph II (PoCC/PoCP) GA 12m treatment No dispute reported 06/30/2026 1220634409
Principal investigator 1 KYOWA KIRIN, INC. $566.05 01/31/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221800722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 01/31/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184151270
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,403.11 01/30/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403369
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,403.11 01/30/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403371
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,403.11 01/30/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404616
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,207.99 01/30/2025 Non-covered Recipient Entity
Pautler Cohen Findlay And Eichenbaum Mds Pa
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406872
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 01/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800660
Principal investigator 1 KYOWA KIRIN, INC. $566.05 01/30/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800667
Principal investigator 1 Novartis Pharmaceuticals Corporation $188,009.34 01/30/2025 Non-covered Recipient Entity
PAULTER COHEN FINDLAY AND EICHENBAUM MDS PA RETINA VITREOUS ASSOCIATES FLORIDA
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration No dispute reported 06/30/2026 1190308434
Principal investigator 1 Ocular Therapeutix, Inc. $50,511.35 01/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236027
Principal investigator 1 Ocular Therapeutix, Inc. $3,014.95 01/29/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236031
Principal investigator 1 Genentech, Inc. $977.93 01/28/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA PAUTLER COHEN FINDLAY & EICHENBAUM
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211646577
Principal investigator 1 KYOWA KIRIN, INC. $5,088.33 01/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800100
Principal investigator 1 KYOWA KIRIN, INC. $5,015.56 01/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800107
Principal investigator 1 KYOWA KIRIN, INC. $8,419.47 01/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800116
Principal investigator 1 KYOWA KIRIN, INC. $5,379.56 01/27/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800124
Principal investigator 1 Ocular Therapeutix, Inc. $15,844.50 01/24/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236023
Principal investigator 1 Ocular Therapeutix, Inc. $12,567.80 01/22/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA DBA RETINA VITREOUS ASSOCIATES OF FL
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236021
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,502,868.63 01/21/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration No dispute reported 06/30/2026 1190301993
Principal investigator 1 Roche TCRC, Inc. $10,975.00 01/21/2025 Non-covered Recipient Entity
Pautler,Cohen,Findlay and Eichenbaum MD's
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211637226
Principal investigator 1 Janssen Research & Development, LLC $27,187.00 01/20/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175392026
Principal investigator 1 Roche TCRC, Inc. $11,207.00 01/14/2025 Non-covered Recipient Entity
Pautler,Cohen,Findlay and Eichenbaum MD's
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211637236
Principal investigator 1 Janssen Research & Development, LLC $5,721.00 01/10/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY & EICHENBAUM MDS PA
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175391886
Principal investigator 1 Novartis Pharmaceuticals Corporation $76,248.18 01/10/2025 Non-covered Recipient Entity
RETINA VITREOUS ASSOCIATES OF FLORIDA
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study No dispute reported 06/30/2026 1190301995
Principal investigator 1 KYOWA KIRIN, INC. $3,809.90 01/09/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221798859
Principal investigator 1 KYOWA KIRIN, INC. $1,106.00 01/09/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221798865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,049.48 01/08/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184146398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,049.48 01/08/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184146400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,049.48 01/08/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184146402
Principal investigator 1 KYOWA KIRIN, INC. $1,904.95 01/06/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221798809
Principal investigator 1 KYOWA KIRIN, INC. $8,577.24 01/06/2025 Non-covered Recipient Entity
PAUTLER COHEN FINDLAY AND EICHENBAUM MDS PA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221798818
Principal investigator 1 Roche TCRC, Inc. $215.74 01/06/2025 Non-covered Recipient Entity
Pautler,Cohen,Findlay and Eichenbaum MD's
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211637233

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $166,174.00 1
PY2024 Value of interest $193,594.00 1
PY2023 Amount invested $18,355.00 1
PY2023 Value of interest $27,418.00 1
PY2022 Amount invested $0.00 2
PY2022 Value of interest $50,000.00 2
PY2021 Amount invested $0.00 2
PY2021 Value of interest $50,866.84 2
PY2020 Amount invested $0.00 2
PY2020 Value of interest $50,866.84 2
PY2019 Amount invested $0.00 2
PY2019 Value of interest $50,866.84 2

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

10 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 US Retina LLC $166,174.00 $193,594.00 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1143634356
PY2023 US Retina LLC $18,355.00 $27,418.00 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1052376953
PY2022 US Retina LLC $0.00 $49,999.99 Shares Physician Covered Recipient No dispute reported 06/30/2026 951870023
PY2022 US Retina LLC $0.00 $0.01 Shares Physician Covered Recipient No dispute reported 06/30/2026 951870045
PY2021 US Retina LLC $0.00 $50,866.83 Shares Physician Covered Recipient No dispute reported 06/30/2026 856669209
PY2021 US Retina LLC $0.00 $0.01 Shares Physician Covered Recipient No dispute reported 06/30/2026 856669245
PY2020 US Retina LLC $0.00 $50,866.83 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311503
PY2020 US Retina LLC $0.00 $0.01 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311541
PY2019 US Retina LLC $0.00 $50,866.83 Shares Physician Covered Recipient No dispute reported 06/30/2026 655843207
PY2019 US Retina LLC $0.00 $0.01 Shares Physician Covered Recipient No dispute reported 06/30/2026 655843285